Roche to divest from biologics manufacturing facility in Vacaville, California
Roche has announced their plans to divest from their legacy Genentech biologics manufacturing facility as part of a larger operations strategy after emailed letters were sent to facility employees informing them of the decision.
Swiss pharmaceutical company Roche has announced plans to sell a drug manufacturing facility in Vacaville, California, which boasts 800 employees. If a suitable buyer cannot be found, Roche has announced plans towards the closure of the plant in 2028/2029.
In a statement, the drugmaker stated plans to divest its legacy Genentech manufacturing facility as part of larger plans to develop broader strategies in the evolution of its manufacturing capabilities to meet therapeutic pipeline requirements. One of the oldest manufacturing sites under the Roche network, the facility specialises in large-scale production of biologics. The facility was purchased over 10 years ago with the purchase of US-based biotech Genentech by Roche. Drug products manufactured at the facility include cancer therapeutics Avastin and Herceptin. Actemra for the treatment of rheumatoid arthritis is also produced at the Vacaville plant. With the onset of the COVID-19 pandemic, Roche collaborated with Regeneron Pharmaceuticals to ramp up supply of Regeneron’s COVID-19 antibody treatment, which was achieved at the Vacaville plant.
In emails sent to employees of the Vacaville facility, the company stated that they did not expect the large volumes of biologics medicines produced by the site to be needed, with production to be shifted to a newer plant. Roche stated their intention to initiate a process of finding a buyer for the site, which is to be announced in due course. If a suitable investor cannot be found, plans will shift to ramping down operations towards a closure in 2028/2029.
Global Head of Pharma Technical Operations at Roche Susanne Hundsbaek-Pedersen stated: “The Vacaville site has a 25-year legacy of producing innovating medicines for millions of patients around the world. We aim to find a buyer who shares our values and respects the contributions and expertise of our colleagues at the facility.” Hundsbaek-Pedersen also assured that there would be no immediate effect to operations or employees: “At this time, there is no impact to operations, or to our employees, and we are committed to treating our colleagues in Vacaville with care and compassion throughout the process.”
Sources:
1. Roche to Divest Legacy Genentech Facility in Vacaville, California, as Part of Long-term Strategy to Evolve Manufacturing Capabilities [Accessed June 1, 2023] https://assets.cwp.roche.com/f/126832/x/41d2555bb3/20230531_roche_to_divest_genentech_facility.pdf
2. Exclusive: Roche looking to sell or shut down California biologic drug plant [Accessed June 1, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/roche-looking-sell-vacaville-california-plant-email-2023-05-31/
Related News
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance